Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2054-2060

  Schinazi, Raymond F ^a   Massud, Ivana ^a   Rapp, Kimberly L ^a   Cristiano, Meta ^a   Detorio, Mervi A ^a   Stanton, Richard A ^a   Bennett, Matthew A ^a   Kierlin Duncan, Monique ^a   Lennerstrand, Johan ^a,b   Nettles, James H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 5 FLUOROCYTIDINE; ABACAVIR; AMDOXOVIR; DIDANOSINE; DNA POLYMERASE; ELVUCITABINE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

ARTICLE; CODON; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHOCYTE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; VIRUS GENOME;

CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79955532742     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01700-10     Document Type: Article

References (47)

1. Berman, H. M., et al. 2000. The protein data bank. Nucleic Acids Res. 28:235-242. (Pubitemid 30047768)
2. Boyer, P. L., T. Imamichi, S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2004. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J. Virol. 78:9987-9997.
3. Clark, A. M., and P. Labute. 2007. 2D depiction of protein-ligand complexes. J. Chem. Infect. Model 47:1933-1944.
4. Das, K., et al. 2009. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem. 284:35092-35100.
5. Deval, J., et al. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516.
6. Erickson-Viitanen, S., et al. 2003. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. Antivir. Chem. Chemother. 14:39-47.
7. Eswar, N., et al. 2006. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinformatics Chapter 5:Unit 5.6.
8. Garforth, S. J., T. W. Kim, M. A. Parniak, E. T. Kool, and V. R. Prasad. 2007. Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the β3-β4 hairpin loop in dNTP selection. J. Mol. Biol. 365:38-49.
9. Geleziunas, R., et al. 2003. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-D-2′,3′-dideoxy- 2′,3′-didehydro-5-fluorocytidine (Reverset). Antivir. Chem. Chemother. 14:49-59.
10. Giri, J., H. J. Rueda, A. Monticelli, and N. Planes. 2000. Case report of a novel amino acid deletion in codon 67 and T69G substitution in the reverse transcriptase of HIV-1. Antivir. Ther. 5:227-228.
11. Hammond, J. L., et al. 2005. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of β-2′, 3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. Antimicrob. Agents Chemother. 49:3930-3932.
12. Hari, M., et al. 2006. Paclitaxel-resistant cells have a mutation in the paclitaxel- binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5:270-278.
13. Henikoff, S., and J. G. Henikoff. 1992. Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. U. S. A. 89:10915-10919.
14. Hernandez-Santiago, B. I., J. S. Mathew, K. L. Rapp, J. P. Grier, and R. F. Schinazi. 2007. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob. Agents Chemother. 51:2130-2135.
15. Herzmann, C., et al. 2005. Safety, pharmacokinetics, and efficacy of (±)-β- 2′,3′-dideoxy-5-fluoro-3′-thiacytidine with efavirenz and stavudine in antiretroviral- naive human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:2828-2833.
16. Hu, Z., et al. 2007. Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J. Acquir. Immune Defic. Syndr. 45:494-500.
17. Huang, G., et al. 2004. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood 103:3200-3207. (Pubitemid 38451699)
18. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
19. Huse, S. M., J. A. Huber, H. G. Morrison, M. L. Sogin, and D. M. Welch. 2007. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 8:R143.
20. Imamichi, T., et al. 2000. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J. Virol. 74:10958-10964. (Pubitemid 32223960)
21. Imamichi, T., M. A. Murphy, H. Imamichi, and H. C. Lane. 2001. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J. Virol. 75:3988-3992.
22. Imamichi, T., et al. 2000. High-level resistance to 3′-azido- 3′-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J. Virol. 74:1023-1028. (Pubitemid 30036242)
23. Johnson, V. A., et al. 2008. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16:138-145.
24. Labute, P. 2008. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 29:1693-1698.
25. Lennerstrand, J., C. K. Chu, and R. F. Schinazi. 2007. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(β-D-dioxolane)thymine triphosphate. Antimicrob. Agents Chemother. 51:2078-2084.
26. Menendez-Arias, L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146.
27. Menendez-Arias, L., T. Matamoros, and C. E. Cases-Gonzalez. 2006. Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness. Curr. Pharm. Des. 12:1811-1825.
28. Mitsuya, Y., et al. 2008. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J. Virol. 82:10747-10755. (Pubitemid 352691166)
29. Needlema, S. B., and C. D. Wunsch. 1970. A general method applicable to search for similarities in amino acid sequence of two proteins. J. Mol. Biol. 48:443-453.
30. Pettersen, E. F., et al. 2004. UCSF chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
31. Ramachandran, G. N., C. Ramakrishnan, and V. Sasisekharan. 1963. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 7:95-99.
32. Roge, B. T., et al. 2003. K65R with or without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine, and stavudine. Antivir. Ther. 8:173-182.
33. Ross, L., et al. 2000. Deletions in the β3-β4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy. J. Hum. Virol. 3:144-149.
34. Schinazi, R. F., D. L. Cannon, B. H. Arnold, and D. Martino-Saltzman. 1988. Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 32:1784-1787.
35. Schinazi, R. F., et al. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
36. Schinazi, R. F., et al. 1990. Activities of 3′-azido-3′- deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 34:1061-1067.
37. Sharma, P. L., J. H. Nettles, A. Feldman, K. Rapp, and R. F. Schinazi. 2009. Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. Antivir. Res. 83:317-323.
38. Sluis-Cremer, N., D. Arion, N. Kaushik, H. Lim, and M. A. Parniak. 2000. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem. J. 348(Pt. 1):77-82.
39. Spira, T. J., et al. 1987. Micromethod for assaying reverse transcriptase of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J. Clin. Microbiol. 25:97-99.
40. Stuyver, L. J., et al. 2004. Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose. Antivir. Ther. 9:529-536.
41. Svarovskaia, E. S., et al. 2008. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48:428-436.
42. Tamalet, C., et al. 2000. Multidrug resistance genotypes (insertions in the β3-β4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 270:310-316. (Pubitemid 30333678)
43. Tuske, S., et al. 2004. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11:469-474.
44. Villena, C., et al. 2007. Relative fitness and replication capacity of a multi-nucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J. Virol. 81:4713-4721. (Pubitemid 46668668)
45. Wang, C., Y. Mitsuya, B. Gharizadeh, M. Ronaghi, and R. W. Shafer. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17:1195-1201.
46. Waters, L., and M. R. Nelson. 2005. New drugs. J. HIV Ther. 10:16-18.
47. White, K. L., et al. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.